Alkem Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 13, 2025, 8:06 pm

Competitors of Alkem Laboratories Ltd

All Competitor Stocks of Alkem Laboratories Ltd

Quarterly Result

Last Updated: August 20, 2025, 2:00 pm

Below is a detailed analysis of the quarterly data for Alkem Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 3,371.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,144.00 Cr. (Mar 2025) to 3,371.00 Cr., marking an increase of 227.00 Cr..
• For Expenses, as of Jun 2025, the value is 2,632.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,752.00 Cr. (Mar 2025) to 2,632.00 Cr., marking a decrease of 120.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 739.00 Cr.. The value appears strong and on an upward trend. It has increased from 391.00 Cr. (Mar 2025) to 739.00 Cr., marking an increase of 348.00 Cr..
• For OPM %, as of Jun 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Mar 2025) to 22.00%, marking an increase of 10.00%.
• For Other Income, as of Jun 2025, the value is 149.00 Cr.. The value appears strong and on an upward trend. It has increased from 146.00 Cr. (Mar 2025) to 149.00 Cr., marking an increase of 3.00 Cr..
• For Interest, as of Jun 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 112.00 Cr. (Mar 2025) to 88.00 Cr., marking a decrease of 24.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 771.00 Cr.. The value appears strong and on an upward trend. It has increased from 396.00 Cr. (Mar 2025) to 771.00 Cr., marking an increase of 375.00 Cr..
• For Tax %, as of Jun 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 18.00% (Mar 2025) to 13.00%, marking a decrease of 5.00%.
• For Net Profit, as of Jun 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 322.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 346.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 55.56. The value appears strong and on an upward trend. It has increased from 25.58 (Mar 2025) to 55.56, marking an increase of 29.98.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:20 pm

Growth

Last Updated: September 4, 2025, 10:45 pm

Balance Sheet

Last Updated: November 9, 2025, 1:36 pm

Below is a detailed analysis of the balance sheet data for Alkem Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
• For Reserves, as of Mar 2025, the value is 11,961.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,288.00 Cr. (Mar 2024) to 11,961.00 Cr., marking an increase of 1,673.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,381.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,418.00 Cr. (Mar 2024) to 1,381.00 Cr., marking a decrease of 37.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 4,325.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,844.00 Cr. (Mar 2024) to 4,325.00 Cr., marking an increase of 481.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 17,691.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,575.00 Cr. (Mar 2024) to 17,691.00 Cr., marking an increase of 2,116.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,852.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,873.00 Cr. (Mar 2024) to 2,852.00 Cr., marking a decrease of 21.00 Cr..
• For CWIP, as of Mar 2025, the value is 548.00 Cr.. The value appears strong and on an upward trend. It has increased from 159.00 Cr. (Mar 2024) to 548.00 Cr., marking an increase of 389.00 Cr..
• For Investments, as of Mar 2025, the value is 1,846.00 Cr.. The value appears strong and on an upward trend. It has increased from 484.00 Cr. (Mar 2024) to 1,846.00 Cr., marking an increase of 1,362.00 Cr..
• For Other Assets, as of Mar 2025, the value is 12,445.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,060.00 Cr. (Mar 2024) to 12,445.00 Cr., marking an increase of 385.00 Cr..
• For Total Assets, as of Mar 2025, the value is 17,691.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,575.00 Cr. (Mar 2024) to 17,691.00 Cr., marking an increase of 2,116.00 Cr..

Notably, the Reserves (11,961.00 Cr.) exceed the Borrowings (1,381.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Alkem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 181.11. This value is within the healthy range. It has increased from 150.19 (Mar 24) to 181.11, marking an increase of 30.92.
• For Diluted EPS (Rs.), as of Mar 25, the value is 181.11. This value is within the healthy range. It has increased from 150.19 (Mar 24) to 181.11, marking an increase of 30.92.
• For Cash EPS (Rs.), as of Mar 25, the value is 215.24. This value is within the healthy range. It has increased from 176.56 (Mar 24) to 215.24, marking an increase of 38.68.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,002.50. It has increased from 896.23 (Mar 24) to 1,002.50, marking an increase of 106.27.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,002.50. It has increased from 896.23 (Mar 24) to 1,002.50, marking an increase of 106.27.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,084.44. It has increased from 1,059.61 (Mar 24) to 1,084.44, marking an increase of 24.83.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 251.43. This value is within the healthy range. It has increased from 213.83 (Mar 24) to 251.43, marking an increase of 37.60.
• For PBIT / Share (Rs.), as of Mar 25, the value is 221.56. This value is within the healthy range. It has increased from 188.79 (Mar 24) to 221.56, marking an increase of 32.77.
• For PBT / Share (Rs.), as of Mar 25, the value is 211.38. This value is within the healthy range. It has increased from 169.23 (Mar 24) to 211.38, marking an increase of 42.15.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 185.36. This value is within the healthy range. It has increased from 151.52 (Mar 24) to 185.36, marking an increase of 33.84.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 181.14. This value is within the healthy range. It has increased from 150.21 (Mar 24) to 181.14, marking an increase of 30.93.
• For PBDIT Margin (%), as of Mar 25, the value is 23.18. This value is within the healthy range. It has increased from 20.18 (Mar 24) to 23.18, marking an increase of 3.00.
• For PBIT Margin (%), as of Mar 25, the value is 20.43. This value exceeds the healthy maximum of 20. It has increased from 17.81 (Mar 24) to 20.43, marking an increase of 2.62.
• For PBT Margin (%), as of Mar 25, the value is 19.49. This value is within the healthy range. It has increased from 15.97 (Mar 24) to 19.49, marking an increase of 3.52.
• For Net Profit Margin (%), as of Mar 25, the value is 17.09. This value exceeds the healthy maximum of 10. It has increased from 14.29 (Mar 24) to 17.09, marking an increase of 2.80.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.70. This value is within the healthy range. It has increased from 14.17 (Mar 24) to 16.70, marking an increase of 2.53.
• For Return on Networth / Equity (%), as of Mar 25, the value is 18.06. This value is within the healthy range. It has increased from 17.41 (Mar 24) to 18.06, marking an increase of 0.65.
• For Return on Capital Employeed (%), as of Mar 25, the value is 19.29. This value is within the healthy range. It has decreased from 19.49 (Mar 24) to 19.29, marking a decrease of 0.20.
• For Return On Assets (%), as of Mar 25, the value is 12.24. This value is within the healthy range. It has increased from 11.52 (Mar 24) to 12.24, marking an increase of 0.72.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.08. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.08, marking a decrease of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.86 (Mar 24) to 0.77, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 2.76. This value is within the healthy range. It has increased from 2.61 (Mar 24) to 2.76, marking an increase of 0.15.
• For Quick Ratio (X), as of Mar 25, the value is 2.02. This value exceeds the healthy maximum of 2. It has increased from 1.94 (Mar 24) to 2.02, marking an increase of 0.08.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has increased from 1.25 (Mar 24) to 4.64, marking an increase of 3.39.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.18. This value is within the healthy range. It has decreased from 29.96 (Mar 24) to 23.18, marking a decrease of 6.78.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 19.90. This value is below the healthy minimum of 20. It has decreased from 25.68 (Mar 24) to 19.90, marking a decrease of 5.78.
• For Earning Retention Ratio (%), as of Mar 25, the value is 76.82. This value exceeds the healthy maximum of 70. It has increased from 70.04 (Mar 24) to 76.82, marking an increase of 6.78.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 80.10. This value exceeds the healthy maximum of 70. It has increased from 74.32 (Mar 24) to 80.10, marking an increase of 5.78.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 24.70. This value is within the healthy range. It has increased from 22.74 (Mar 24) to 24.70, marking an increase of 1.96.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 19.21. This value is within the healthy range. It has increased from 18.20 (Mar 24) to 19.21, marking an increase of 1.01.
• For Enterprise Value (Cr.), as of Mar 25, the value is 58,288.87. It has decreased from 59,097.05 (Mar 24) to 58,288.87, marking a decrease of 808.18.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has decreased from 4.67 (Mar 24) to 4.50, marking a decrease of 0.17.
• For EV / EBITDA (X), as of Mar 25, the value is 19.39. This value exceeds the healthy maximum of 15. It has decreased from 23.12 (Mar 24) to 19.39, marking a decrease of 3.73.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has decreased from 4.66 (Mar 24) to 4.50, marking a decrease of 0.16.
• For Retention Ratios (%), as of Mar 25, the value is 76.81. This value exceeds the healthy maximum of 70. It has increased from 70.03 (Mar 24) to 76.81, marking an increase of 6.78.
• For Price / BV (X), as of Mar 25, the value is 4.87. This value exceeds the healthy maximum of 3. It has decreased from 5.73 (Mar 24) to 4.87, marking a decrease of 0.86.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has decreased from 4.66 (Mar 24) to 4.50, marking a decrease of 0.16.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness